718630-59-2 | Butanamide, 3-​methyl-​N-​[1,​4,​5,​6-​tetrahydro-​6,​6-​dimethyl-​5-​[(1-​methyl-​4-​piperidinyl)​carbonyl]​pyrrolo[3,​4-​c]​pyrazol-​3-​yl]​-

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$23.00	$16.00
2mg	98%	in stock	$32.00	$22.00
5mg	98%	in stock	$48.00	$33.00
10mg	98%	in stock	$69.00	$48.00
25mg	98%	in stock	$160.00	$112.00
50mg	98%	in stock	$185.00	$129.00
100mg	98%	in stock	$295.00	$206.00
250mg	98%	in stock	$483.00	$338.00

Description

• Catalog Number: AC52971
• Chemical Name: Butanamide, 3-​methyl-​N-​[1,​4,​5,​6-​tetrahydro-​6,​6-​dimethyl-​5-​[(1-​methyl-​4-​piperidinyl)​carbonyl]​pyrrolo[3,​4-​c]​pyrazol-​3-​yl]​-
• CAS Number: 718630-59-2
• Molecular Formula: C19H31N5O2
• Molecular Weight: 361.48173999999995
• MDL Number: MFCD17169992
• SMILES: CC(CC(=O)Nc1n[nH]c2c1CN(C2(C)C)C(=O)C1CCN(CC1)C)C

Computed Properties

• Complexity: 542
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 4
• XLogP3: 1

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.

  Cell cycle (Georgetown, Tex.) 20110315

• An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.

  Cell cycle (Georgetown, Tex.) 20110101

• Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study.

  Molecular cancer therapeutics 20100501

• Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.

  Bioorganic & medicinal chemistry 20100301